Tuesday, December 4, 2018, San Antonio, Texas, 7:30 PM – 10:00 PM

Addressing Current Questions and Controversies in the Management of Early and Advanced Breast Cancer

San Antonio Marriott Rivercenter
101 Bowie Street
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

7:30 PM – 10:00 PM — Educational Dinner Meeting

Meeting Room:
Grand Ballroom (Third Floor)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Javier Cortes, MD, PhD
Head, Breast Cancer Program
Vall d’Hebron University Hospital
Vall d’Hebron Institute of Oncology
Barcelona, Spain

William J Gradishar, MD
Betsy Bramsen Professor of Breast Oncology and Professor of Medicine
Deputy Director, Clinical Network
Robert H Lurie Comprehensive Cancer Center of Northwestern University
Director, Maggie Daley Center for Women’s
Cancer Care
Interim Chief, Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Joyce O’Shaughnessy, MD
Chair, Breast Cancer Research Program
Baylor Charles A Sammons Cancer Center
Celebrating Women Chair in Breast Cancer Research
Texas Oncology
US Oncology
Dallas, Texas

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical
Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Debu Tripathy, MD
Professor of Internal Medicine
Director, Komen UT Southwestern Breast Cancer Research Program
University of Texas Southwestern Medical Center
Dallas, Texas

Neil Love, MD
Research To Practice
Miami, Florida

Six investigators will serve as the faculty for this symposium, which will be divided into 6 modules focused on addressing practical issues commonly encountered by clinicians across distinct areas of breast cancer (BC) management. To accomplish this goal, prior to the event we will recruit 5 general oncologists to participate in a closed planning session to introduce key questions and challenging cases from their practices. With this information providing the basis for the agenda, the meeting will employ short didactic presentations, interactive audience polling and extensive moderated panel discussion to provide perspectives on emerging research and address real-world concerns voiced by the consulting clinicians.

Topics for Discussion
  • Neoadjuvant, Adjuvant and Extended Adjuvant Therapy for Patients with Localized HER2-Positive BC
  • Use of Genomic Classifiers to Assist in Clinical Decision-Making for Patients with ER-Positive Early BC
  • Selection and Sequence of Therapy for Patients with ER-Positive, HER2-Negative Metastatic BC (mBC); Ongoing Trials of CDK4/6 Inhibitors for Localized ER-Positive Disease
  • Long-Term Management of HER2-Positive mBC; Treatment of HER2-Positive Brain Metastases; Novel Agents
  • Available Research Data with and Ongoing Evaluation of Immune Checkpoint Inhibition in BC
  • Novel Targeted Agents and Other Emerging Therapeutic Strategies
A detailed agenda will be made available in the early fall.

Target Audience:
This activity is intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Consider published data to guide the use of biomarkers and genomic classifiers to assess risk and customize therapy for patients with hormone receptor-positive breast cancer (BC) in the neoadjuvant, adjuvant and extended-adjuvant settings.
  • Appraise available and emerging research evidence to individualize the selection and duration of neoadjuvant, adjuvant and/or extended adjuvant therapy for patients with HER2-overexpressing early BC.
  • Implement a long-term clinical plan for the care of patients with metastatic HER2-positive BC, incorporating existing and investigational targeted treatments.
  • Develop an evidence-based algorithm for the treatment of advanced hormone receptor-positive pre-and postmenopausal BC, including the use of endocrine, biologic and chemotherapeutic agents.
  • Consider published research findings and patient preferences in the selection and sequencing of available and investigational therapeutic agents for metastatic ER/PR-negative, HER2-negative BC.
  • Appraise the biologic rationale for, available data with and potential clinical roles of novel immunotherapeutic approaches in preparation for their potential introduction into future BC practice.
  • Identify ongoing trials of other investigational approaches in BC, and refer eligible patients and obtain consent for study participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, Genomic Health Inc, Lilly, Merck, Puma Biotechnology Inc and Seattle Genetics.

San Antonio Marriott Rivercenter
101 Bowie Street
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room:
Grand Ballroom (Third Floor)

The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center.


This activity is intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

NOTICE: Registration for this event is independent of registration for the San Antonio Breast Cancer Symposium.